What AOA does

AOA Dx is a US-based biotech company founded in 2020 and headquartered in Denver, Colorado, that develops liquid biopsy diagnostics for early cancer detection in women. Its lead product, AKRIVIS GD™, is a blood test intended for early detection of ovarian cancer in symptomatic women, addressing a clinical gap where the existing CA125 standard detects roughly 50% of early-stage cases and average diagnostic delay is approximately nine months. Underlying the test is the proprietary GlycoLocate™ platform, which combines lipidomics, metabolomics, and proteomics — including tumor-marker gangliosides (GD2, GD3) — with machine learning classifiers trained on a biobank of more than 2,200 patient samples.

The company is building its pipeline on an exclusive license to ganglioside-related IP from McGill University, a filed US patent (Application No. 63,087,427), and validated clinical performance of 92-94.8% early-stage sensitivity across independent US and UK cohorts. AOA Dx operates its own CLIA-capable laboratory in Denver, runs the multi-center OVERT prospective trial in the US and the APEX biobank-expansion study, and pursues a parallel laboratory-developed test (LDT) launch and FDA clearance pathway. Strategic partners include the University of Colorado Anschutz Medical Campus, the University of Manchester / Manchester University NHS Foundation Trust, Brigham and Women's Hospital (where Dr. Kevin Elias serves as OVERT Principal Investigator), BLOODPAC, and Sonrai Analytics for AI/data infrastructure.

AOA Dx has raised approximately $24 million across pre-seed, seed, and Series A rounds from investors including Joyance Partners, Avestria Ventures, Y Combinator, Good Growth Capital, Labcorp Venture Fund, and RH Capital. The company is pre-revenue with no commercial product on market; its go-to-market is built around diagnostic testing services delivered through its CLIA lab to healthcare providers (gynecologic oncologists, OB/GYNs, and primary care physicians) evaluating women with vague abdominal and pelvic symptoms suggestive of ovarian cancer. The company is seeking approximately $30 million in additional capital to bring AKRIVIS GD™ to market.

Name

AOA

Legal name

AOA Dx Inc.

Website

https://aoadx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

AOA Dx is a US biotech developing AKRIVIS GD™, a multi-omic liquid biopsy blood test using machine learning on ganglioside and lipid biomarkers to detect early-stage ovarian cancer in symptomatic women, supported by its proprietary GlycoLocate™ platform and an in-house CLIA lab.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

Keywords

• Liquid biopsy diagnostics
• Ovarian cancer detection
• Multi-omics biomarker
• Women's health diagnostics
• Early cancer screening

Headquarters

HQ city

Denver

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: AOA Dx plans to commercialize its AKRIVIS GD™ diagnostic test as a laboratory-developed test (LDT) and through FDA-cleared device pathway. Revenue will be generated from clinical laboratory testing services provided to healthcare providers evaluating women with symptoms suggestive of ovarian cancer.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

AOA Dx develops and commercializes liquid biopsy blood tests for the early detection of cancers affecting women, anchored by AKRIVIS GD™, a first-in-class multi-omics blood test that detects early-stage ovarian cancer through proprietary tumor-marker ganglioside (GD2/GD3) biomarkers analyzed via LC-MS and machine learning. The test is delivered through the company's own CLIA-certified laboratory in Denver and is targeted at healthcare providers evaluating symptomatic women. The underlying discovery engine, GlycoLocate™, is an AI-enabled multi-omics platform combining lipidomics, metabolomics, proteomics, and clinical data to develop diagnostic assays across multiple cancer indications.

Product overview

AOA Dx offers a unified product portfolio built on its proprietary GlycoLocate™ AI-enabled multi-omics platform. The platform serves as the core technology engine, integrating lipids, metabolites, proteins, and clinical data using machine learning for early cancer detection. The primary commercial product emerging from this platform is AKRIVIS GD™, a first-of-its-kind liquid biopsy test for early detection of ovarian cancer in symptomatic women. GlycoLocate™ functions as the underlying discovery and analytical engine, while AKRIVIS GD™ represents the first clinical application of this technology targeting ovarian cancer diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• GlycoLocate™: AI-enabled early detection cancer platform utilizing lipidomics to unlock next-generation biomarkers for early cancer diagnosis
• AKRIVIS GD™

Products and services

• AKRIVIS GD™ AKRIVIS GD™ is a first-of-its-kind liquid biopsy blood test that uses a multi-omics approach combining tumor-associated gangliosides (GD2, GD3), lipids, metabolites, and proteins with AI and machine learning to detect early-stage ovarian cancer in symptomatic women. The test is delivered through AOA Dx's own CLIA-certified laboratory and targets healthcare providers (gynecologic oncologists, OB/GYNs, and primary care physicians) evaluating women with symptoms suggestive of ovarian cancer. Clinical performance: 92-94.8% sensitivity for early-stage detection, 94.4% sensitivity across all stages and subtypes, and 96.5% sensitivity / 80.6% specificity in symptomatic cohorts.

Quantifiable outcome

• 92% early-stage (Stage I/II) sensitivity for ovarian cancer detection in symptomatic women, nearly double the ~50% sensitivity of CA125
• +5 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Six partnerships are on record, tiered strategic, core and minor.

• Sonrai AnalyticsstrategicTechnology or Integration · 20 May 2025Strategic collaboration leveraging Sonrai's AI-powered cloud-based advanced analytics platform to integrate and analyze multi-modal data (multi-omic and clinical data) for biomarker validation and diagnostic accuracy enhancement. Sonrai provides bioinformatics expertise, pre-built machine learning tools, and secure cloud environment with role-based access for regulatory compliance.
• University of Colorado Anschutz Medical Campus - Ovarian Cancer Innovations Group (OCIG)coreStrategic or Co-development Partner · 29 April 2025Multi-year research collaboration providing clinically annotated patient samples and study design expertise. OCIG cohort used for multi-omic model training; demonstrated AUC of 93% for all-stage and 91% for early-stage ovarian cancer detection in approximately 500 samples.
• The University of Manchester / Manchester University NHS Foundation TrustcoreStrategic or Co-development Partner · 29 April 2025Independent testing set partner providing prospectively collected symptomatic samples from intended-use population. Achieved AUC of 92% for all-stage and 88% for early-stage disease in real-world clinical cohort, validating robustness of AOA's approach.
• BLOODPAC ConsortiumcoreStrategic or Co-development Partner · 20 February 2025Public-private consortium aimed at accelerating development, validation, and accessibility of liquid biopsy assays. AOA Dx participating in Multi-Omics and Early Detection Working Groups, contributing lipidomic research and multi-omics expertise to establish standards for early detection assays.
• Professor Uri Saragovi (McGill University / Lady Davis Institute)coreTechnology or Integration · 30 August 2021Exclusive license agreement to suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies. Prof. Saragovi serves as scientific advisor and inventor; has published over 200 publications and 21 patents focusing on translational medicine and ganglioside targeting.
• Dr. Anne-Marie Mes-Masson (Centre hospitalier de l'Université de Montréal)minorStrategic or Co-development Partner · 1 January 2020Research collaboration on tumor-ganglioside screening studies for early cancer detection. Awarded RQRM grant supporting initial validation that gangliosides are accurate and reliable markers for early-stage cancer diagnosis.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• GRAIL: GRAIL developed Galleri, a multi-cancer early-detection blood test using methylation-based liquid biopsy and machine learning. Directly comparable to AOA Dx as a liquid biopsy company pursuing early cancer detection via novel biomarker classes plus advanced analytics, though GRAIL focuses on pan-cancer screening vs. AOA's symptomatic ovarian indication.
• Guardant Health: Guardant Health offers Guardant Shield for CRC screening and other liquid biopsy oncology tests using cfDNA. Comparable as a commercial-stage liquid biopsy company leveraging ML and proprietary chemistry to displace legacy screening/diagnostic modalities, with broader oncology portfolio than AOA Dx.
• Freenome: Freenome is developing a multi-omics blood test for early cancer detection combining cfDNA, proteins, and ML — closely paralleling AOA Dx's GlycoLocate multi-omics approach. Both target early detection in asymptomatic/symptomatic populations and have raised hundreds of millions in venture funding.
• BillionToOne: BillionToOne developed UNITY Fetal Risk Screen and Northstar liquid biopsy products using proprietary molecular counting and ML approaches. Comparable as a venture-backed diagnostics company using novel molecular biology plus data science to address oncology/prenatal indications, with overlapping target markets in women's health.
• Natera: Natera commercializes Signatera (tumor-informed MRD testing) and Empower (prenatal screening). Comparable as a liquid biopsy company with established CLIA lab operations, FDA-cleared diagnostics, and active pursuit of oncology indications through proprietary chemistry and ML.

Broad incumbents

• Exact Sciences: Exact Sciences commercializes Cologuard (CRC screening) and acquired Thrive Earlier Detection for its multi-cancer blood test. Comparable as a dominant liquid biopsy/screening diagnostics incumbent with deep commercial infrastructure. AOA Dx's CSO previously led R&D at Exact Sciences subsidiary Thrive, indicating direct talent and methodological overlap.

Emerging players

• Personal Genome Diagnostics (PGDx): PGDx (acquired by Labcorp) developed NGS-based liquid biopsy assays for cancer. Direct comparable as an NGS/multi-omics liquid biopsy developer; notably, AOA Dx's Sr. Director of R&D and Director of R&D both previously led assay development at PGDx, indicating direct talent overlap and methodological kinship.
• Bluestar Genomics: Bluestar Genomics developed epigenomic liquid biopsy tests for early cancer detection using 5-hydroxymethylcytosine biomarkers with ML. Comparable as an emerging multi-cancer/oncology liquid biopsy company pursuing novel biomarker classes plus ML analytics, though focused on different epigenetic markers than AOA's lipidomics approach.
• Adela: Adela is developing a multi-cancer detection blood test using cell-free methylated DNA plus ML. Comparable as a venture-backed emerging liquid biopsy company pursuing early cancer detection through novel biomarker chemistry and machine learning, with similar pre-commercial/validation stage.
• Angle plc: Angle plc developed Parsortix, a liquid biopsy system for capturing circulating tumor cells across multiple cancer indications. Comparable as an emerging liquid biopsy company targeting multiple oncology indications with proprietary sample-prep technology plus downstream analysis, addressing similar physician and laboratory customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AOA_Dx
• LinkedInlinkedin.com/company/aoadx
• Instagraminstagram.com/aoa_dx

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds5 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AOA